Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 11:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 167 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Enbrel Clear all
Completed Phase 2 Interventional

Treatment of Resistant Langerhans Cell Histiocytosis With ENBREL

NCT00048373
View directory record Official record
Conditions
Histiocytosis, Langerhans-Cell
Interventions
Etanercept
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Day to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Oct 19, 2026, 11:45 AM EDT
Completed Phase 4 Interventional Results available

Study Comparing Etanercept and Methotrexate vs. Methotrexate Alone in Rheumatoid Arthritis

NCT00195494
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Etanercept, Methotrexate, Placebo
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 5, 2012 · Synced Oct 19, 2026, 11:45 AM EDT
Withdrawn Phase 4 Interventional

Human Tumor Necrosis Factor Alpha (TNFa)-Induced Pre-B Cell Bone Marrow Emigrants

NCT01009879
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Etanercept
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 2, 2013 · Synced Oct 19, 2026, 11:45 AM EDT
Completed Phase 3 Interventional Results available

Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis

NCT01690299
View directory record Official record
Conditions
Psoriasis, Psoriatic Arthritis
Interventions
Apremilast, Etanercept, Placebo tablet, Placebo injection
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
31
States / cities
Phoenix, Arizona • Bakersfield, California • Irvine, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 19, 2026, 11:45 AM EDT
Completed Early Phase 1 Interventional

Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D

NCT05281614
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Etanercept, Vedolizumab
Drug
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
La Jolla, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Oct 19, 2026, 11:45 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet

NCT00585650
View directory record Official record
Conditions
Psoriasis
Interventions
Etanercept, Placebo injections
Biological · Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Irvine, California • Winston-Salem, North Carolina • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Oct 19, 2026, 11:45 AM EDT
Recruiting Phase 3 Interventional

Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis

NCT06654882
View directory record Official record
Conditions
Polyarticular Course Juvenile Idiopathic Arthritis (JIA)
Interventions
TNFi (Tumor Necrosis Factor inhibitor) medication, Abatacept, Tocilizumab, Tofacitinib
Drug
Lead sponsor
Duke University
Other
Eligibility
2 Years to 21 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
San Francisco, California • Gainesville, Florida • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 19, 2026, 11:45 AM EDT
Completed Phase 4 Interventional Results available

Treatments Against RA and Effect on FDG-PET/CT

NCT02374021
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Methotrexate, Sulfasalazine, Hydroxychloroquine, Etanercept, Adalimumab
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
45 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
31
States / cities
Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Oct 19, 2026, 11:45 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Etanercept and Gemcitabine in Patients With Advanced, Chemotherapy Naive Pancreatic Adenocarcinoma

NCT00201838
View directory record Official record
Conditions
Pancreatic Neoplasms, Adenocarcinoma
Interventions
Gemcitabine, Etanercept
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 30, 2017 · Synced Oct 19, 2026, 11:45 AM EDT
Completed Phase 2 Interventional Results available

A Randomized, Double Blind, Placebo Controlled Study of Etanercept in Children With Kawasaki Disease

NCT00841789
View directory record Official record
Conditions
Mucocutaneous Lymph Node Syndrome, Kawasaki Disease
Interventions
Etanercept, Placebo
Drug
Lead sponsor
Michael Portman
Other
Eligibility
2 Months to 20 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
7
States / cities
New Hyde Park, New York • New York, New York • The Bronx, New York + 4 more
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 19, 2026, 11:45 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)

NCT01597245
View directory record Official record
Conditions
Psoriasis
Interventions
80 mg ixekizumab Dosing Regimen, 50 mg etanercept, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
41
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2020 · Synced Oct 19, 2026, 11:45 AM EDT
Completed Phase 2 Interventional

Etanercept to Treat Wegener's Granulomatosis

NCT00001901
View directory record Official record
Conditions
Vasculitis, Wegener's Granulomatosis
Interventions
Etanercept
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 19, 2026, 11:45 AM EDT
Completed Phase 2 Interventional Results available

A 6-month Randomised, Double-blind, Open Arm Comparator, Phase IIb, With AZD9056, in Patients With Rheumatoid Arthritis (RA)

NCT00520572
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
AZD9056, Etanercept, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Aventura, Florida • Orlando, Florida • Sarasota, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 19, 2026, 11:45 AM EDT
Completed Phase 4 Interventional Results available

A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors

NCT01331837
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Etanercept, Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
3,080 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
143
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 125 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2017 · Synced Oct 19, 2026, 11:45 AM EDT
Completed Not applicable Interventional Results available

Preoperative Etanercept Before Inguinal Hernia Surgery

NCT00825344
View directory record Official record
Conditions
Inguinal Hernia, Postoperative Pain
Interventions
Etanercept, Saline
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Oct 19, 2026, 11:45 AM EDT
Withdrawn No phase listed Observational

Circadian RA Study in Rheumatoid Arthritis Subjects

NCT03178955
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Etanercept
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2019 · Synced Oct 19, 2026, 11:45 AM EDT
Completed Not applicable Interventional

Study of TNF-Antagonism in Metabolic Syndrome

NCT00409318
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Etanercept, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2008 · Synced Oct 19, 2026, 11:45 AM EDT
Completed Phase 2 Interventional

Study of Etanercept (Enbrel) in the Treatment of Pemphigus Vulgaris

NCT00135720
View directory record Official record
Conditions
Pemphigus Vulgaris
Interventions
Enbrel (Etanercept)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 19, 2026, 11:45 AM EDT
Completed Phase 1 Interventional Results available

Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) to Measure Response to Etanercept in Rheumatoid Arthritis

NCT00361634
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Etanercept
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Los Angeles, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Oct 19, 2026, 11:45 AM EDT
Completed No phase listed Observational

Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab)

NCT05320159
View directory record Official record
Conditions
Psoriasis
Interventions
Secukinumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
17,743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 1, 2022 · Synced Oct 19, 2026, 11:45 AM EDT
Completed Early Phase 1 Interventional

Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body Myositis

NCT00802815
View directory record Official record
Conditions
Inclusion Body Myositis
Interventions
Etanercept
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced Oct 19, 2026, 11:45 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

The Safety and Efficacy of Etanercept (Enbrel®) for the Treatment of Discoid Lupus Erythematosus

NCT00797784
View directory record Official record
Conditions
Discoid Lupus Erythematosus (DLE)
Interventions
etanercept(Enbrel®)
Drug
Lead sponsor
Florida Academic Dermatology Centers
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 26, 2010 · Synced Oct 19, 2026, 11:45 AM EDT
Recruiting Phase 2 Interventional

TNF-α Treatment of Blast-Induced Tinnitus

NCT04066348
View directory record Official record
Conditions
Tinnitus, Noise Induced
Interventions
Etanercept, Saline
Biological · Other
Lead sponsor
Wayne State University
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
4
States / cities
Celebration, Florida • Coral Gables, Florida • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 19, 2026, 11:45 AM EDT
Completed Phase 3 Interventional Results available

Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)

NCT01004432
View directory record Official record
Conditions
Arthritis, Arthritis, Rheumatoid, Autoimmune Diseases
Interventions
Golimumab 50 mg SC, Golimumab 2 mg/kg IV, Methotrexate (MTX), Placebo SC, Placebo IV
Drug
Lead sponsor
Janssen Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
89
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 86 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 19, 2026, 11:45 AM EDT